



# STIC Search Report

## EIC 1700

STIC Database Tracking Number: 196099

**TO: Deborah Lambkin**  
**Location: REM/5B09/5C18**  
**Art Unit : 1626**  
**July 26, 2006**

**Case Serial Number: 10/821705**

**From: Mei Huang**  
**Location: EIC 1700**  
**REMSSEN 4B28**  
**Phone: 571/272-3952**  
**Mei.huang@uspto.gov**

### Search Notes

Examiner Lambkin,

Please feel free to contact me if you have any questions or if you would like to refine the search query,

Thank you for using STIC services!

Mei Huang



## SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Deborah Samblan Examiner #: 71300 Date: 7/20/06  
 Art Unit: 1626 Phone Number: 302-0693 Serial Number: 10/821,705  
 Mail Box and Bldg/Room Location: 5C18/5209 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

\*\*\*\*\*

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: \_\_\_\_\_

Inventors (please provide full names): \_\_\_\_\_

Earliest Priority Filing Date: \_\_\_\_\_



\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

*please search genes of C1*

*+ species of claim 8*

*genus*

*species*



*see attachments*

*Please exclude inventors*

*Thanks*

## STAFF USE ONLY

## Type of Search

## Vendors and cost where applicable

Searcher: MAH NA Sequence (#) \_\_\_\_\_ STN ☒ \_\_\_\_\_  
 Searcher Phone #: \_\_\_\_\_ AA Sequence (#) \_\_\_\_\_ Dialog \_\_\_\_\_  
 Searcher Location: \_\_\_\_\_ Structure (#) 3 Questel/Orbit \_\_\_\_\_  
 Date Searcher Picked Up: \_\_\_\_\_ Bibliographic \_\_\_\_\_ Dr. Link \_\_\_\_\_  
 Date Completed: 7/25/06 Litigation \_\_\_\_\_ Lexis/Nexis \_\_\_\_\_  
 Searcher Prep & Review Time: \_\_\_\_\_ Fulltext \_\_\_\_\_ Sequence Systems \_\_\_\_\_  
 Clerical Prep Time: \_\_\_\_\_ Patent Family \_\_\_\_\_ WWW/Internet \_\_\_\_\_  
 Online Time: \_\_\_\_\_ Other \_\_\_\_\_ Other (specify) \_\_\_\_\_

10/821, 705

17669 (AP)


30

5

# CLAIMS

What is claimed is:

1. A compound comprising



10

or a pharmaceutically acceptable salt or a prodrug thereof,


wherein

the dashed line represents the presence or absence of a double bond;

J is  $C=O$  or  $CHOH$ ;

- 15 A is  $-(CH_2)_6-$ , or *cis*  $-CH_2CH=CH-(CH_2)_3-$ , wherein 1 or 2 carbons may be substituted with S or O;

B is  $CO_2H$ , or  $CO_2R$ ,  $CONR_2$ ,  $CONHCH_2CH_2OH$ ,  $CON(CH_2CH_2OH)_2$ ,  $CH_2OR$ ,  $P(O)(OR)_2$ ,  $CONRSO_2R$ ,  $SONR_2$ , or



C/P/S/G

- 20 R is H,  $C_{1-6}$  alkyl;


D is  $-(CH_2)_n-$ ,  $-X(CH_2)_n$ , or  $-(CH_2)_nX-$ , wherein n is from 0 to 3 and X is S or O; and

E is an aromatic or heteroaromatic moiety having from 0 to 4 substituents, said substituents each comprising from 1 to 6 non-hydrogen atoms.


- 25 2. The compound of claim 1 comprising



7. The compound of claim 1 comprising



8. The compound of claim 1 comprising:



9. The compound of claim 1 comprising



# STIC Search Results Feedback Form

**EIC17000**

Questions about the scope or the results of the search? Contact *the EIC searcher* or contact:

Kathleen Fuller, EIC 1700 Team Leader  
571/272-2505 REMSEN 4B28

## Voluntary Results Feedback Form

- I am an examiner in Workgroup:  Example: 1713
- Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature  
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to EIC1700 REMSEN 4B28

=> fil reg

FILE 'REGISTRY' ENTERED AT 17:28:05 ON 25 JUL 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUL 2006 HIGHEST RN 895581-37-0  
DICTIONARY FILE UPDATES: 25 JUL 2006 HIGHEST RN 895581-37-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d his

(FILE 'HOME' ENTERED AT 13:47:21 ON 25 JUL 2006)

FILE 'HCAPLUS' ENTERED AT 13:47:41 ON 25 JUL 2006  
E US20050228185/PN

L1 1 S E3  
SEL RN

L2 FILE 'REGISTRY' ENTERED AT 13:49:21 ON 25 JUL 2006  
10 S E1-10

FILE 'REGISTRY' ENTERED AT 14:07:21 ON 25 JUL 2006

L3 STR  
L4 STR L3  
L5 STR L4  
L6 STR L5  
L7 5 S L6  
L8 1377 S L6 FUL  
SAV L8 LAM705/A  
L9 3 S L2 AND L8  
L10 STR L6  
L11 40 S L10 SSS SAM SUB=L8  
L12 1 S L2 AND C25H29CLO5S  
L13 STR L10  
L14 0 S L13 SSS SAM SUB=L8  
L15 2 S L13 SSS FUL SUB=L8  
SAV L15 LAM705S1/A  
L16 11 S C25H29CLO5S/MF  
L17 2 S L8 AND L16

*claim 8 compound*

FILE 'HCAPLUS' ENTERED AT 16:41:44 ON 25 JUL 2006  
L18 1 S L15  
L19 2 S L17

L20 2 S L18 OR L19



FILE 'REGISTRY' ENTERED AT 16:43:01 ON 25 JUL 2006

L21 STR L13  
 L22 0 S L21 SSS SAM SUB=L8  
 L23 STR L10  
 L24 47 S L23 SSS SAM SUB=L8  
 L25 STR L23  
 L26 39 S L25 SSS SAM SUB=L8  
 L27 2 S L21 SSS FUL SUB=L8  
 L28 2 S L15 OR L27  
 SAV L26 LAM705S2/A

FILE 'REGISTRY' ENTERED AT 17:28:05 ON 25 JUL 2006

=> d l15 que stat

L6 STR



OH@32

VAR G1=13/15/18/21/23/24/27/30

VPA 32-1/5/4/3 U

VPA 7-1/5/4/3 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS SAT AT 13

GGCAT IS UNS AT 14

GGCAT IS SAT AT 16

GGCAT IS UNS AT 17

GGCAT IS SAT AT 18

GGCAT IS UNS AT 20

GGCAT IS UNS AT 22

GGCAT IS UNS AT 23

GGCAT IS SAT AT 25

GGCAT IS UNS AT 26

GGCAT IS SAT AT 27

GGCAT IS UNS AT 29

GGCAT IS UNS AT 31

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 2







NUMBER OF NODES IS 31

STEREO ATTRIBUTES: NONE

L8 1377 SEA FILE=REGISTRY SSS FUL L6

L13 STR


Ak~Cy @13 14      S~Ak~Cy @15 16 17      Ak~S~Cy @18 19 20      S~Cy @21 22      Cy @23      O~Cy @30 31



G2 @48

Ak~G3  
 @49 50

Cy @51



VAR G1=13/15/18/21/23/24/27/30

VAR G2=7/33/38/43

VAR G3=C/P/S/51

VPA 48-5/4/3 U

VPA 49-5/4/3 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS SAT AT 13

GGCAT IS UNS AT 14

GGCAT IS SAT AT 16

GGCAT IS UNS AT 17

GGCAT IS SAT AT 18

GGCAT IS UNS AT 20

GGCAT IS UNS AT 22

GGCAT IS UNS AT 23

GGCAT IS SAT AT 25

GGCAT IS UNS AT 26

GGCAT IS SAT AT 27

GGCAT IS UNS AT 29

GGCAT IS UNS AT 31

GGCAT IS UNS AT 51

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS E6 C AT 49

GRAPH ATTRIBUTES:

RSPEC 2

NUMBER OF NODES IS 50

STEREO ATTRIBUTES: NONE

L15 2 SEA FILE=REGISTRY SUB=L8 SSS FUL L13



100.0% PROCESSED 227 ITERATIONS  
SEARCH TIME: 00.00.02

2 ANSWERS

=> fil hcap

FILE 'HCAPLUS' ENTERED AT 17:28:40 ON 25 JUL 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jul 2006 VOL 145 ISS 5  
FILE LAST UPDATED: 24 Jul 2006 (20060724/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l20 ibib abs hitstr hitind 1-2

L20 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:1103380 HCAPLUS  
DOCUMENT NUMBER: 143:367143  
TITLE: Preparation of 10-hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists  
INVENTOR(S): Donde, Yariv  
PATENT ASSIGNEE(S): Allergan, Inc., USA  
SOURCE: U.S. Pat. Appl. Publ., 16 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

*The current application*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005228185	A1	20051013	US 2004-821705	20040409
WO 2005100339	A1	20051027	WO 2005-US10124	20050325

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,

KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC,  
NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2004-821705

A

200404

09

OTHER SOURCE(S): MARPAT 143:367143  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Compd. I [dashed line = the presence or absence of a double bond; J = C=O, O, CHOH; A is (CH<sub>2</sub>)<sub>6</sub>, or cis CH<sub>2</sub>CH=CH(CH<sub>2</sub>)<sub>3</sub>, wherein 1 or 2 carbons may be substituted with S or O; B is CO<sub>2</sub>H, CO<sub>2</sub>R, CONR<sub>2</sub>, CONHCH<sub>2</sub>CH<sub>2</sub>OH, CON(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, CH<sub>2</sub>OR, P(O)(OR)<sub>2</sub>, CONRSO<sub>2</sub>R, SONR<sub>2</sub>, 1-R-tetrazol-5-yl; R = H, C1-6-alkyl; D = (CH<sub>2</sub>)<sub>n</sub>, X(CH<sub>2</sub>)<sub>n</sub>, or (CH<sub>2</sub>)<sub>n</sub>X; n = 0 to 3; X = S, O; and E = arom. or heteroarom. moiety having from 0 to 4 substituents, said substituents each comprising from 1 to 6 non-hydrogen atoms] or a pharmaceutically acceptable salt or a prodrug thereof, is disclosed herein. Thus, prostaglandin analog II was prepd. from cyclopentenone III (TBDMS = Si Me<sub>2</sub>CMe<sub>3</sub>) via cuprate addn. of benzothiazole IV (TBDMS = Si Me<sub>2</sub>CMe<sub>3</sub>), desilylation/dehydration with AcOH in aq. THF, conjugate redn. with [Ph<sub>3</sub>PCuH]<sub>6</sub>, enol silylation with LDA/TMSCl, epoxidn./hydrolysis with dimethyldioxirane followed by pyridinium tosylate in aq. THF, desilylation with pyridinium hydrofluoride and enzymic hydrolysis with rabbit liver esterase. Methods, compns., and medicaments related thereto, as well as exptl. results showing prostaglandin EP<sub>4</sub> selective agonist activity for certain compds. disclosed herein, are also disclosed. The binding affinity of II to prostaglandin receptors was detd. [K<sub>i</sub> = 170-200 nM vs. EP<sub>4</sub> receptor].

IT 866453-12-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
RACT (Reactant or reagent)


(prepn. and enzymic hydrolysis of; prepn. of 10-hydroxy-11-  
dihydroprostaglandin analogs as selective EP<sub>4</sub> agonists)

RN 866453-12-5 HCAPLUS

CN 5-Heptenoic acid, 7-[(1R,5R)-5-[(1E)-5-(3-chlorobenzo[b]thien-2-yl)-  
3-hydroxy-1-pentenyl]-3-hydroxy-2-oxocyclopentyl]-, methyl ester,  
(5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




IT 866453-13-6P

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity);  
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological  
 study); PREP (Preparation); USES (Uses)  
 (prepn. of 10-hydroxy-11-dihydroprostaglandin analogs as  
 selective EP4 agonists)

RN 866453-13-6 HCAPLUS

CN 5-Heptenoic acid, 7-[(1R,5R)-5-[(1E)-5-(3-chlorobenzo[b]thien-2-yl)-  
 3-hydroxy-1-pentenyl]-3-hydroxy-2-oxocyclopentyl]-, (5Z)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



IC ICM A61K031-558

ICS C07D049-02; C07F009-28; C07D333-52

INCL 548253000; 554214000; 562008000; 562459000; 549049000

CC 26-3 (Biomolecules and Their Synthetic Analogs)

IT 866453-12-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
 RACT (Reactant or reagent)  
 (prepn. and enzymic hydrolysis of; prepn. of 10-hydroxy-11-  
 dihydroprostaglandin analogs as selective EP4 agonists)

IT 866453-13-6P

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity);  
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological  
 study); PREP (Preparation); USES (Uses)  
 (prepn. of 10-hydroxy-11-dihydroprostaglandin analogs as  
 selective EP4 agonists)

L20 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2002:888568 HCAPLUS

DOCUMENT NUMBER: 137:369893

TITLE: Preparation of prostanoid acid derivatives as  
 ocular hypotensive agents

INVENTOR(S): Burk, Robert M.; Gac, Todd S.  
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA  
 SOURCE: PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092099	A1	20021121	WO 2002-US14580	20020507
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002177620	A1	20021128	US 2001-859770	20010517
US 6531504	B2	20030311		
CA 2446994	AA	20021121	CA 2002-2446994	20020507
EP 1390036	A1	20040225	EP 2002-746356	20020507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004530687	T2	20041007	JP 2002-589016	20020507
US 2003105155	A1	20030605	US 2002-294521	20021113
US 6670485	B2	20031230		
PRIORITY APPLN. INFO.:			US 2001-859770	A 20010517
			WO 2002-US14580	W 20020507
OTHER SOURCE(S):		MARPAT 137:369893		
GI				



AB The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amt. of prostanoid acid derivs. Title compds. (I) [wavy line attachments indicate either  $\alpha$  or  $\beta$  configuration; dashed bonds represent a double bond or a single bond; D = a covalent bond, CH<sub>2</sub>, O, S, NH; X = CO<sub>2</sub>R, CONR<sub>2</sub>, CH<sub>2</sub>OR, P(O)(OR)<sub>2</sub>, CONRSO<sub>2</sub>R, SONR<sub>2</sub>, tetrazolyl; Y = O, OH, OCOR<sub>2</sub>, halogen, cyano; Z = CH<sub>2</sub>, a covalent bond; R = H, R<sub>2</sub>; R<sub>1</sub> = H, R<sub>2</sub>, Ph, COR<sub>2</sub>; R<sub>2</sub> = alkyl, alkenyl; R<sub>3</sub> = (un)substituted benzothieryl, benzofuranyl, naphthyl], are prep'd. Thus, prostanoid acid deriv. (II) was prep'd. via a multistep synthetic sequence starting from 7-[(1R,2R,3R,5S)-2-formyl-3,5-bis[(tetrahydro-2H-pyran-2-yl)oxy]cyclopentyl]-methyl-(5Z)-heptenoate and [4-(3-chlorobenzo[b]thien-2-yl)-2-oxobutyl]-phosphonic acid di-Me ester. The prep'd. compds. were tested and formulated.

IT 475467-34-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of prostanoid acid derivs. as ocular hypotensives)

RN 475467-34-6 HCAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3R)-2-[(1E,3S)-5-(3-chlorobenzo[b]thien-2-yl)-3-hydroxy-1-pentenyl]-3-hydroxy-5-oxocyclopentyl]-, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



IC ICM A61K031-5575

ICS A61P027-06; C07C405-00

CC 26-3 (Biomolecules and Their Synthetic Analogs)

Section cross-reference(s): 1, 63

IT 25151-81-9DP, Prostanoid acid, derivs. 475467-34-6P

475467-35-7P 475467-36-8P 475467-37-9P 475467-38-0P

475467-39-1P 475467-40-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(prepn. of prostanoic acid derivs. as ocular hypotensives)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN  
THE RE FORMAT

=>

Sample Search on  
a broadened query.

=&gt; d l10 que stat

L6 STR

Ak~Cy  
@13 14S~Ak~Cy  
@15 16 17Ak~S~Cy  
@18 19 20S~Cy  
@21 22O~Ak~Cy  
@24 25 26Ak~O~Cy  
@27 28 29O~Cy  
@30 31

OH @32

VAR G1=13/15/18/21/23/24/27/30

VPA 32-1/5/4/3 U

VPA 7-1/5/4/3 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS SAT AT 13

GGCAT IS UNS AT 14

GGCAT IS SAT AT 16

GGCAT IS UNS AT 17

GGCAT IS SAT AT 18

GGCAT IS UNS AT 20

GGCAT IS UNS AT 22

GGCAT IS UNS AT 23

GGCAT IS SAT AT 25

GGCAT IS UNS AT 26

GGCAT IS SAT AT 27

GGCAT IS UNS AT 29

GGCAT IS UNS AT 31

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 2

NUMBER OF NODES IS 31

STEREO ATTRIBUTES: NONE

L7 1377 SEA FILE=REGISTRY SSS FUL L6

L9 STR

L9  
Ak~Cy  
@13 14


S~Ak~Cy  
@15 16 17

Ak~S~Cy  
@18 19 20

S~Cy  
@21 22

Cy @23






O~Cy  
@30 31



O~Ak~Cy  
@24 25 26

Ak~O~Cy  
@27 28 29

OH @32 G2 @48



None: in this query -OH could be attached to different positions.

VAR G1=13/15/18/21/23/24/27/30

VAR G2=7/33/38/43

VAR G3=C/P/S/54

VPA 32-5/4/3 U

VPA 48-5/4/3 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS SAT AT 13

GGCAT IS UNS AT 14

GGCAT IS SAT AT 16

GGCAT IS UNS AT 17

GGCAT IS SAT AT 18

GGCAT IS UNS AT 20

GGCAT IS UNS AT 22

GGCAT IS UNS AT 23

GGCAT IS SAT AT 25

GGCAT IS UNS AT 26

GGCAT IS SAT AT 27

GGCAT IS UNS AT 29

GGCAT IS UNS AT 31

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS E6 C AT 52

GRAPH ATTRIBUTES:

RSPEC 1

NUMBER OF NODES IS 54

STEREO ATTRIBUTES: NONE

L10 39 SEA FILE=REGISTRY SUB=L7 SSS SAM L9

100.0% PROCESSED

69 ITERATIONS

39 ANSWERS




SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):	ONLINE	**COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):	882 TO	1878
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):	406 TO	1154

=&gt; d sca

L10 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Cyclopentaneheptanoic acid, 2-(4,4-difluoro-3-oxo-4-phenoxybutyl)-3-hydroxy-5-oxo-, methyl ester, [1R-(1 $\alpha$ ,2 $\beta$ ,3 $\alpha$ )]-(9CI)  
 MF C23 H30 F2 O6

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 5-Heptenoic acid, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-, 4-nitrophenyl ester, [1R-[1 $\alpha$ (Z),2 $\beta$ (1E,3R\*),3 $\alpha$ )]-(9CI)  
 MF C28 H31 N O8


Absolute stereochemistry.  
 Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4,5-Heptadienoic acid, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-, monosodium salt (9CI)  
 MF C22 H26 O6 . Na




● Na

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 5-Heptenoic acid, 7-[2-[6-(3,6-dihydro-4-methyl-1(2H)-pyridinyl)-3-hydroxy-6-oxo-1-hexenyl]-3-hydroxy-5-oxocyclopentyl]- (9CI)  
 MF C24 H35 N O6

PAGE 1-A



PAGE 2-A




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 5-Heptenoic acid, 7-[2-[3-(4H-1,3-benzodioxin-2-yl)-3-hydroxypropyl]-  
 3-hydroxy-5-oxocyclopentyl]-, methyl ester, [1R-  
 [1 $\alpha$ (Z),2 $\beta$ [R\*(R\*)],3 $\alpha$ ]]- (9CI)  
 MF C24 H32 O7

Absolute stereochemistry.  
 Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 5-Heptenoic acid, 7-[3-hydroxy-2-(3-hydroxy-3-methyl-4-phenylbutyl)-  
 5-oxocyclopentyl]-, [1,1'-biphenyl]-4-yl ester, [1R-  
 [1 $\alpha$ (Z),2 $\beta$ (S\*),3 $\alpha$ ]]- (9CI)  
 MF C35 H40 O5

Absolute stereochemistry.  
 Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0